BRAF Non-V600 Mutations in Metastatic Colorectal Cancer

被引:1
作者
Liu, Junjia [1 ]
Xie, Hao [2 ]
机构
[1] Albert Einstein Coll Med, Bronx, NY 10461 USA
[2] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
关键词
BRAF non-V600 mutation; colorectal cancer; targeted therapy; heterogeneity; 1ST-LINE TREATMENT; KRAS MUTATIONS; COLON-CANCER; WILD-TYPE; RAF; SURVIVAL; VEMURAFENIB; INHIBITION; ACTIVATION; GENOMICS;
D O I
10.3390/cancers15184604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Metastatic Colorectal cancer (CRC) is an aggressive and complex disease influenced by gene changes, including BRAF mutations. While previous work has largely spotlighted the BRAF V600 mutation, there remains much to uncover about its lesser-studied non-V600 counterparts. Through examining their characteristics, clinical relevance, and emerging treatment possibilities, this review bridges some knowledge gaps and paints a clearer picture of the BRAF non-V600 mutations. By understanding these intricacies, healthcare professionals and researchers can be better equipped to explore targeted treatments, potentially enhancing care for metastatic CRC patients.Abstract Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the United States. Despite advancements in detection and therapeutic options, patients with metastatic CRC continue to face poor survival rates. The heterogeneity of oncogenic alterations, including BRAF mutations, poses a substantial challenge in identifying optimal treatment approaches. Notably, BRAF non-V600 mutations, encompassing class II and class III mutations, exhibit the distinct patterns of the signaling pathways and responses to targeted therapies compared to BRAF V600 mutations (class I). Nevertheless, the current classification system may underestimate the complexity and heterogeneity of BRAF-mutant CRC. Ongoing clinical trials are actively investigating targeted therapies for BRAF non-V600 mutations, but they are being confronted with patient recruitment obstacles due to the genetic diversity of these alterations. Continued research is needed to refine mutation subtyping, identify effective treatment strategies, and improve outcomes for patients with BRAF non-V600-mutant CRC. Enhancing our understanding and management of this specific subgroup of CRC is crucial for developing personalized treatment approaches and advancing patient care. This manuscript provides a comprehensive overview of the recent advances in and perspectives on BRAF non-V600 alterations in colorectal cancer, including relevant ongoing clinical trials.
引用
收藏
页数:12
相关论文
共 50 条
[21]   BRAF V600E Mutation in Colorectal Cancer Is Associated with Right-sided Tumours and Iron Deficiency Anaemia [J].
Sideris, Michail ;
Adams, Katie ;
Moorhead, Jane ;
Diaz-Cano, Salvador ;
Bjarnason, Ingvar ;
Papagrigoriadis, Savvas .
ANTICANCER RESEARCH, 2015, 35 (04) :2345-2350
[22]   BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer [J].
Ros, Javier ;
Baraibar, Iosune ;
Sardo, Emilia ;
Mulet, Nuria ;
Salva, Francesc ;
Argiles, Guillem ;
Martini, Giulia ;
Ciardiello, Davide ;
Cuadra, Jose Luis ;
Tabernero, Josep ;
Elez, Elena .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[23]   KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer [J].
Li, Hong-Tao ;
Lu, Yuan-Yuan ;
An, Yan-Xin ;
Wang, Xin ;
Zhao, Qing-Chuan .
ONCOLOGY REPORTS, 2011, 25 (06) :1691-1697
[24]   Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer [J].
Kopetz, S. ;
Grothey, A. ;
Yaeger, R. ;
Van Cutsem, E. ;
Desai, J. ;
Yoshino, T. ;
Wasan, H. ;
Ciardiello, F. ;
Loupakis, F. ;
Hong, Y. S. ;
Steeghs, N. ;
Guren, T. K. ;
Arkenau, H. -T. ;
Garcia-Alfonso, P. ;
Pfeiffer, P. ;
Orlov, S. ;
Lonardi, S. ;
Elez, E. ;
Kim, T. -W. ;
Schellens, J. H. M. ;
Guo, C. ;
Krishnan, A. ;
Dekervel, J. ;
Morris, V. ;
Calvo Ferrandiz, A. ;
Tarpgaard, L. S. ;
Braun, M. ;
Gollerkeri, A. ;
Keir, C. ;
Maharry, K. ;
Pickard, M. ;
Christy-Bittel, J. ;
Anderson, L. ;
Sandor, V. ;
Tabernero, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17) :1632-1643
[25]   Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study [J].
Gallois, C. ;
Bergen, E. S. ;
Auclin, E. ;
Pernot, S. ;
Higue, J. ;
Trouilloud, I. ;
Touchefeu, Y. ;
Turpin, A. ;
Mazard, T. ;
Sartore-Bianchi, A. ;
Prenen, H. ;
Alberti, A. ;
Pilla, L. ;
Cuissy, S. ;
Wookey, V. ;
Perret, A. ;
Melchior, C. ;
Artru, P. ;
Dubreuil, O. ;
Drouillard, A. ;
Doat, S. ;
Lavole, J. ;
Basile, D. ;
Perkins, G. ;
Jary, M. ;
Stintzing, S. ;
Jos, J. ;
Tougeron, D. ;
Taieb, J. .
ESMO OPEN, 2024, 9 (09)
[26]   Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments [J].
Ros, J. ;
Matito, J. ;
Villacampa, G. ;
Comas, R. ;
Garcia, A. ;
Martini, G. ;
Baraibar, I. ;
Saoudi, N. ;
Salva, F. ;
Martin, A. ;
Antista, M. ;
Toledo, R. ;
Martinelli, E. ;
Pietrantonio, F. ;
Boccaccino, A. ;
Cremolini, C. ;
Dientsmann, R. ;
Tabernero, J. ;
Vivancos, A. ;
Elez, E. .
ANNALS OF ONCOLOGY, 2023, 34 (06) :543-552
[27]   A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study [J].
Loupakis, Fotios ;
Intini, Rossana ;
Cremolini, Chiara ;
Orlandi, Armando ;
Sartore-Bianchi, Andrea ;
Pietrantonio, Filippo ;
Pella, Nicoletta ;
Spallanzani, Andrea ;
Dell'Aquila, Emanuela ;
Scartozzi, Mario ;
De Luca, Emmanuele ;
Rimassa, Lorenza ;
Formica, Vincenzo ;
Leone, Francesco ;
Calvetti, Lorenzo ;
Aprile, Giuseppe ;
Antonuzzo, Lorenzo ;
Urbano, Federica ;
Prenen, Hans ;
Negri, Francesca ;
Di Donato, Samantha ;
Buonandi, Pasquale ;
Tomasello, Gianluca ;
Avallone, Antonio ;
Zustovich, Fable ;
Moretto, Roberto ;
Antoniotti, Carlotta ;
Salvatore, Lisa ;
Calegari, Maria Alessandra ;
Siena, Salvatore ;
Morano, Federica ;
Ongaro, Elena ;
Cascinu, Stefano ;
Santini, Daniele ;
Ziranu, Pina ;
Schirripa, Marta ;
Buggin, Federica ;
Prete, Alessandra Anna ;
Depetris, Ilaria ;
Biason, Paola ;
Lonardi, Sara ;
Zagonel, Vittorina ;
Fassan, Matteo ;
Di Maio, Massimo .
EUROPEAN JOURNAL OF CANCER, 2019, 118 :121-130
[28]   Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations [J].
Negrao, Marcelo, V ;
Raymond, Victoria M. ;
Lanman, Richard B. ;
Robichaux, Jacqulyne P. ;
He, Junqin ;
Nilsson, Monique B. ;
Ng, Patrick K. S. ;
Amador, Bianca E. ;
Roarty, Emily B. ;
Nagy, Rebecca J. ;
Banks, Kimberly C. ;
Zhu, Viola W. ;
Ng, Chun ;
Chae, Young Kwang ;
Clarke, Jeffrey M. ;
Crawford, Jeffrey A. ;
Meric-Bernstam, Funda ;
Ou, Sai-Hong Ignatius ;
Gandara, David R. ;
Heymach, John, V ;
Bivona, Trever G. ;
McCoach, Caroline E. .
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (10) :1611-1623
[29]   Targeting BRAF V600E in metastatic colorectal cancer: where are we today? [J].
Guerrero, Rodrigo Motta ;
Labajos, Veronica Arnao ;
Ballena, Sophia Lozano ;
Macha, Carlos Aliaga ;
Lezama, Miguel Sotelo ;
Roman, Cristian Pacheco ;
Beltran, Paola Montenegro ;
Torrejon, Alejandro Figueroa .
ECANCERMEDICALSCIENCE, 2022, 16
[30]   A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation [J].
Sereno, Maria ;
Moreno, Victor ;
Moreno Rubio, Juan ;
Gomez-Raposo, Cesar ;
Garcia Sanchez, Sagrario ;
Hernandez Jusdado, Rebeca ;
Falagan, Sandra ;
Zambrana Tebar, Francisco ;
Casado Saenz, Enrique .
ANTI-CANCER DRUGS, 2015, 26 (09) :1004-1007